Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

msh id	COM:BARINTHUSBIO
symbol	BRNS
name	Barinthus Biotherapeutics plc
homepage url	https://www.barinthusbio.com
country	GB
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	130
crunchbase url	-
linkedin url	-
founders	-

market cap	55.9M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.78
growth cost of revenue	-
growth depreciation and amortization	-1
growth ebitda	-17.16
growth ebitda ratio	-901.87
growth eps	-
growth eps diluted	-
growth general and administrative expenses	5.23
growth gross profit	-0.98
growth gross profit ratio	-

BRNS

COM:BARINTHUSBIO

Barinthus Biotherapeutics plc

Last Close

0.90

21/11 21:00

Market Cap

39.76M

Beta: -

Volume Today

39.75K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	84.72M
cost of revenue	84.72M
depreciation and amortization	-
ebitda	-83.91M
ebitda ratio	-104.63
eps	-1.91K
eps diluted	-1.91K
operating expenses	84.72M
operating income	-83.91M
operating income ratio	-104.63

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-52.3M
inventory	-
working capital ttm	144.31M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-